LY3127760, a Selective Prostaglandin E4 (EP4) Receptor Antagonist, and Celecoxib: A Comparison of Pharmacological Profiles

Safety, tolerability, and pharmacology profiles of LY3127760, an EP4 antagonist, were explored in healthy subjects in a subject/investigator‐blind, parallel‐group, multiple‐ascending dose study. Cohorts consisted of 13 patients randomized to LY3127760, celecoxib (400 mg), or placebo (9:2:2 ratio) fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Yan, Smith, Claire, Hu, Leijun, Coutant, David E., Whitehurst, Kelly, Phipps, Krista, McNearney, Terry Ann, Yang, Xiao, Ackermann, Bradley, Pottanat, Thomas, Landschulz, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759725/
https://www.ncbi.nlm.nih.gov/pubmed/28857461
http://dx.doi.org/10.1111/cts.12497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759725/
https://www.ncbi.nlm.nih.gov/pubmed/28857461
http://dx.doi.org/10.1111/cts.12497

Ejemplares similares